Dianthus Therapeutics

formerly DianthusIPO

Developing Next-Generation Therapies For Severe Autoimmune Diseases

Dianthus Therapeutics was founded in 2021, is headquartered in New York, United States, lists 11–50 employees, and has $400.0M in recorded funding across 3 rounds.

Headquarters
New York, New York
Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$400.0M
Last Round
$288.0M Venture RoundSep 2023
Rounds
3
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 4 investors for this company. The full record is or through the API.

About

Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation complement-targeted antibody therapies for severe autoimmune and inflammatory diseases. Its lead candidate, claseprubart (DNTH103), is engineered with extended half-life and high selectivity for active C1s complement protein, enabling self-administered subcutaneous injections. A second candidate, DNTH212, is a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation.

Summary

Dianthus Therapeutics is a Biotech company based in New York, United States, founded in 2021. It lists 11–50 employees. It has raised $400.0M in total across 3 rounds, most recently a $288.0M Venture Round in Sep 2023. Investors include 5AM Ventures, Bain Capital Life Sciences and Avidity Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundSep 2023
$288.0M

Sign up to see all 3 events

Funding: Seed through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Dianthus Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/dianthus-therapeutics"><img src="https://indexed.vc/api/badge/company/dianthus-therapeutics" alt="Dianthus Therapeutics on Indexed.vc" width="260" height="76" /></a>